• The number of people aged 65 or older living with AD in the countries under study will increase by 45% over the forecast period, from 13.1 million in 2016 to 19 million in 2026.

Table of contents

  • Alzheimer's Disease - Epidemiology - Emerging Markets

Author(s): Nishant Kumar, MPH

Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects.

His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.


Related Reports

Alzheimer's Disease - Landscape & Forecast - Disease Landscape & Forecast

View Details

Alzheimer's Disease - Epidemiology - Mature Markets

DRG Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key...

View Details

Alzheimer's Disease - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

For the estimated 3.4 million people in the United States with Alzheimer’s disease (AD), approved pharmacotherapy is limited to four procognitive symptomatic agents (e.g., donepezil, memantin...

View Details